University of Texas MD Anderson Cancer Center, Houston, TX;
Funda Meric-Bernstam , Antoine Hollebecque , Junji Furuse , Do-Youn Oh , John A. Bridgewater , Masashi Shimura , Bailey Anderson , Nanae Hangai , Volker Wacheck , Lipika Goyal
Background: Futibatinib, a covalently binding FGFR1–4 inhibitor, showed a 42% objective response rate with a 9.7 mo median duration of response in pts with advanced intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions/rearrangements in the phase 2 FOENIX-CCA2 trial. Futibatinib treatment (tx) was safe and tolerable with a predictable and manageable side effect profile. This pooled retrospective analysis examined mgmt of futibatinib-associated AEs in pts with advanced tumors, including iCCA. Methods: Pts from a global phase 1/2 study (NCT02052778) and a Japanese phase 1 study (JapicCTI-142552) who received futibatinib 20 mg QD (recommended dose) were included. Futibatinib dose modifications and supportive medications (meds) for AE mgmt were analyzed for futibatinib-associated AEs of clinical interest (group terms: hyperphosphatemia, hepatic AEs, retinal disorders, nail disorders, rash, palmar plantar erythrodysesthesia [PPE], cataract). The Kaplan-Meier method was used for time-to-resolution (TTR) analysis. Results: As of October 1, 2020, 318 pts with advanced solid tumors (60% CCA; 98% with ≥1 prior tx) had received ≥1 futibatinib 20 mg QD dose (median tx duration, 3.6 mo). Table includes incidence and mgmt of key AEs of clinical interest. Hyperphosphatemia was the most frequent cause of futibatinib dose modifications; 85% and 30% of pts with hyperphosphatemia received phosphate binders and/or phosphaturic agents, respectively, with no obvious TTR differences. Other common supportive meds included analgesics (in 55% of pts with nail disorders; 71% with PPE) and corticosteroids (37% of pts with rash). Retinal disorders occurred in 8% of pts (all grade [gr] 1-2 and resolved). Cataract, a late-onset AE on continued tx, occurred in 12 (4%; 4 [1%] gr ≥3) pts, leading to dose modifications in 3 pts. One pt underwent cataract surgery and resumed futibatinib tx the next day. Discontinuations due to tx-related AEs were rare (2.5%) and included 1 pt each with retinal detachment, onycholysis, and cataract. Conclusions: This analysis of AE mgmt showed a consistent and manageable safety profile for futibatinib in pts with pretreated advanced tumors. Commonly observed AEs with futibatinib were well managed with dose adjustments and supportive meds and rarely led to tx discontinuation. Clinical trial information: NCT02052778/JapicCTI-142552.
AE (group term) | Any-gr AE, n (%) | Gr ≥3 AEs, n (%) | Median time to onset, d | Dose interruptions, n (%) | Dose reductions, n (%) | Supportive meds, n (%) | Resolved, n/N | Median TTR, d |
---|---|---|---|---|---|---|---|---|
Hyperphosphatemia | 280 (88) | 75 (24) | 5.0 | 67 (21) | 41 (13) | 248 (78) | 73/75a | 7 |
Nail disorders | 94 (30) | 4 (1) | 85.0 | 13 (4) | 10 (3) | 74 (23) | 2/4a | NE |
Hepatic AEs | 94 (30) | 38 (12) | 15.5 | 29 (9) | 21 (7) | 0 | 34/38a | 7 |
PPE | 48 (15) | 11 (3) | 85.0 | 15 (5) | 18 (6) | 44 (14) | 11/11a | 8 |
Retinal disorders | 27 (8) | 0 | 40.0 | 4 (1) | 5 (2) | 0 | 6/6b | 23 |
Rash | 27 (8) | 0 | 43.0 | 0 | 0 | 13 (4) | 4/5b | 15 |
NE, not estimable aGr ≥3 resolved to gr <3 bGr 2 resolved to gr <2
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Hope S. Rugo
2020 ASCO Virtual Scientific Program
First Author: Lipika Goyal
2021 ASCO Annual Meeting
First Author: Alison M. Schram
2022 ASCO Genitourinary Cancers Symposium
First Author: Vadim S Koshkin